The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.

Including the name of the #1 company to buy.

Alex Levit Biography and Net Worth

Insider of Context Therapeutics

Alex Levit joined Context in April 2021 as Chief Legal Officer and serves as Corporate Secretary. Prior to joining the Company, Mr. Levit served as Vice President, Deputy General Counsel and Assistant Corporate Secretary of OptiNose, a publicly-traded specialty pharmaceutical company. Prior to OptiNose, Mr. Levit served as Associate General Counsel of Teva Pharmaceuticals, a global pharmaceuticals company, from 2010 until 2017. During his tenures at OptiNose and Teva, Mr. Levit negotiated various in-bound and out-bound licenses, collaborations, mergers and acquisitions, and supply agreements. While at OptiNose, Mr. Levit also handled various public and private financing transactions. Before joining Teva, Mr. Levit was a corporate and life sciences attorney at the law firm of Reed Smith LLP. Mr. Levit also serves as a member of the board of directors of Strados Labs, a medical device company. Mr. Levit holds a JD from Temple University Beasley School of Law and a Bachelor of Arts in Labor & Industrial Relations from Pennsylvania State University, where he is a graduate of the Schreyer Honors College.

What is Alex C. Levit's net worth?: The estimated net worth of Alex C. Levit is at least $14,670.00 as of December 9th, 2022. Mr. Levit owns 9,000 shares of Context Therapeutics stock worth more than $14,670 as of November 21st. This net worth evaluation does not reflect any other assets that Mr. Levit may own. Additionally, Mr. Levit receives a salary of $483,830.00 as Insider at Context Therapeutics. Learn More about Alex C. Levit's net worth.
How old is Alex C. Levit?: Mr. Levit is currently 45 years old. There are 2 older executives and no younger executives at Context Therapeutics. The oldest executive at Context Therapeutics is Ms. Jennifer Minai-Azary, CFO & Treasurer, who is 46 years old. Learn More on Alex C. Levit's age.
What is Alex C. Levit's salary?: As the Insider of Context Therapeutics Inc., Mr. Levit earns $483,830.00 per year. There are 2 executives that earn more than Mr. Levit. The highest earning executive at Context Therapeutics is Mr. Martin A. Lehr, Co-Founder, President, CEO & Director, who commands a salary of $674,080.00 per year. Learn More on Alex C. Levit's salary.
How do I contact Alex C. Levit?: The corporate mailing address for Mr. Levit and other Context Therapeutics executives is 3675 Market Street, Philadelphia, Pennsylvania 19104. Context Therapeutics can also be reached via phone at 267-225-7416 and via email at [email protected]. Learn More on Alex C. Levit's contact information.
Has Alex C. Levit been buying or selling shares of Context Therapeutics?: Alex C. Levit has not been actively trading shares of Context Therapeutics within the last three months. Most recently, on Friday, December 9th, Alex C. Levit bought 6,000 shares of Context Therapeutics stock. The stock was acquired at an average cost of $0.85 per share, with a total value of $5,100.00. Following the completion of the transaction, the insider now directly owns 9,000 shares of the company's stock, valued at $7,650. Learn More on Alex C. Levit's trading history.
Who are Context Therapeutics' active insiders?: Context Therapeutics' insider roster includes Martin Lehr (CEO), and Alex Levit (Insider). Learn More on Context Therapeutics' active insiders.

Alex C. Levit Insider Trading History at Context Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/9/2022	Buy	6,000	$0.85	$5,100.00	9,000
10/22/2021	Buy	3,000	$5.00	$15,000.00

Alex C. Levit Buying and Selling Activity at Context Therapeutics

Context Therapeutics Company Overview

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Today's Range

Now: $1.54

$1.51

$1.58

50 Day Range

MA: $2.02

$1.63

$2.35

2 Week Range

Now: $1.54

$0.77

$2.75

Volume

80,205 shs

Average Volume

303,403 shs

Market Capitalization

$115.58 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.25

Financial Prophecy

From Porter & Company | Ad